- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01263002
A Study With Clevudine Monotherapy or Adefovir and Clevudine Combination in Proportion to Roadmap Concept in Patients With HBV Associated-HCC
December 16, 2014 updated by: Bukwang Pharmaceutical
An Open Study to Evaluate the Efficacy, Safety and Sustained Effect of Clevudine Monotherapy or Adefovir and Clevudine Combination in Proportion to Roadmap Concept in Patients With Chronic Hepatitis B Associated Hepatocellular Carcinoma
An open study to evaluate the Efficacy, Safety of Clevudine monotherapy or Adefovir and Clevudine combination in Proportion to Roadmap Concept in patients with chronic hepatitis B Associated Hepatocellular Carcinoma
Study Overview
Status
Completed
Intervention / Treatment
Study Type
Interventional
Enrollment (Anticipated)
33
Phase
- Phase 4
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Seoul, Korea, Republic of
- Seoul National University Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria
- Patient with chronic HBV DNA and/or with symptoms of liver cirrhosis
- Patient with Hepatocellular carcinoma evidenced by sonography, CT scan, or MRI scan)
- Patient is 18 years and older.
Patient is documented to be HBsAg positive for > 6 months.
- Laboratory report proving HBsAg positive or HBeAg positive for at least six months
- IgM anti-HBc negative, IgG anti-HBc positive at screening
- Patient is HBV DNA positive with DNA levels ≥ 2,000 IU/mL within 30 days of baseline.
- Patient has ALT or AST levels >=40 IU/L
- Cell carcinoma/hepatocellular carcinoma patient who is anticipated to live at least 1 year.
- Patient who is fully active, able to carry on all pre-disease performance without restriction or restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, e.g., light house work, office work.
- Patient who is classified as NYHA functional classification grade 1-2. (NYHA;New York Heart Association)
- Patient who is able to give written informed consent prior to study start and to comply with the study requirements.
Exclusion Criteria
- Patient is currently receiving antiviral therapy.
- Patients previously treated with interferon, peg-interferon or other immunomodulatory within the previous 6 months.
- Patients previously treated with clevudine, lamivudine, adefovir, entecavir, telbivudine, tenofovir or any other investigational nucleoside for HBV infection.
- Patient is coinfected with HCV, HDV or HIV.
- Patient with metastatic malignancy.
- Patient with previous liver transplantation
- Patient is pregnant or breast-feeding.
- Patient has a clinically relevant history of abuse of alcohol or drugs.
- Patient use oriental medicine within the previous 2 weeks.
- Patient has a significant immunocompromised, gastrointestinal, renal, hematological, psychiatric, bronchopulmonary, biliary diseases excluding asymptomatic GB stone, neurological, cardiac, oncologic(except HCC)or allergic disease or medical illness that in the investigator's opinion might interfere with therapy.
- Patient has creatinine clearance less than 60mL/min as estimated by the following formula: (140-age in years) (body weight [kg])/(72) (serum creatinine [mg/dL]) [Note: multiply estimates by 0.85 for women]
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Proportion of patients with HBV DNA levels < 60 IU/mL
Time Frame: 48 week
|
48 week
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
June 1, 2010
Primary Completion (Actual)
January 1, 2013
Study Completion (Actual)
September 1, 2013
Study Registration Dates
First Submitted
December 17, 2010
First Submitted That Met QC Criteria
December 17, 2010
First Posted (Estimate)
December 20, 2010
Study Record Updates
Last Update Posted (Estimate)
December 18, 2014
Last Update Submitted That Met QC Criteria
December 16, 2014
Last Verified
December 1, 2014
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Digestive System Diseases
- Virus Diseases
- Infections
- Blood-Borne Infections
- Communicable Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Neoplasms by Site
- Adenocarcinoma
- Neoplasms, Glandular and Epithelial
- Digestive System Neoplasms
- Liver Diseases
- Hepatitis, Viral, Human
- Hepadnaviridae Infections
- DNA Virus Infections
- Liver Neoplasms
- Carcinoma
- Hepatitis B
- Hepatitis
- Carcinoma, Hepatocellular
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Antiviral Agents
- Reverse Transcriptase Inhibitors
- Nucleic Acid Synthesis Inhibitors
- Enzyme Inhibitors
- Adefovir
- Clevudine
Other Study ID Numbers
- CLV-413
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hepatitis B Associated Hepatocellular Carcinoma
-
SCG Cell Therapy Pte. Ltd.RecruitingHepatocellular Carcinoma Recurrent | Hepatitis B Virus Related Hepatocellular CarcinomaUnited States, Singapore, Hong Kong
-
National Taiwan University HospitalAstraZeneca; Ministry of Science and Technology, Taiwan, ROCRecruitingAdvanced Hepatocellular CarcinomaTaiwan
-
Jia FanSciClone PharmaceuticalsUnknownCurable Hepatitis B Virus-Related Hepatocellular CarcinomaChina
-
Zhongshan Hospital (Xiamen), Fudan UniversityRecruitingHepatocellular Carcinoma | Chronic Hepatitis BChina
-
A2 Healthcare Taiwan CorporationGoldenMed BioTechnologyWithdrawnHepatocellular Carcinoma | Liver Fibrosis | HEPATITIS B CHRONICTaiwan
-
CHA UniversityDong-A ST Co., Ltd.UnknownStudy of Entecavir for Reducing the Risk of Hepatocellular Carcinoma in Chronic Hepatitis B PatientsChronic Hepatitis BKorea, Republic of
-
Third Affiliated Hospital, Sun Yat-Sen UniversityUnknown
-
Taipei Veterans General Hospital, TaiwanUnknownHepatocellular Carcinoma | Chronic Hepatitis BTaiwan
-
National Taiwan University HospitalNot yet recruitingHepatocellular Carcinoma | Radiotherapy | Biomarker | Hepatitis b Virus
-
Taichung Veterans General HospitalGilead Sciences; Taipei Institute of PathologyTerminatedHepatocellular Carcinoma | Chronic Hepatitis BTaiwan
Clinical Trials on clevudine, Adefovir
-
Bukwang PharmaceuticalCompleted
-
Bukwang PharmaceuticalCompletedChronic Hepatitis BKorea, Republic of
-
Bukwang PharmaceuticalTerminatedChronic Hepatitis BKorea, Republic of
-
Inje UniversityBukwang PharmaceuticalTerminatedChronic Hepatitis BKorea, Republic of
-
Bukwang PharmaceuticalCompletedPatients With LC-BKorea, Republic of
-
Bukwang PharmaceuticalCompletedHBeAg(-) Chronic Hepatitis B With Compensated Liver FunctionKorea, Republic of
-
PharmassetTerminatedHepatitis B | Chronic HepatitisUnited States, Canada, China, Argentina, Taiwan, Spain, Puerto Rico, Australia, Greece, Thailand, United Kingdom
-
PharmassetTerminatedHepatitis B | Chronic HepatitisUnited States, Canada, Argentina, Taiwan, Spain, Puerto Rico, Australia, Greece, Thailand, United Kingdom, Brazil, China
-
Bukwang PharmaceuticalTerminatedHepatitis BKorea, Republic of